To Advance Clinical Research, Azenta Partners with the Crohn's & Colitis Foundation

Azenta Life Sciences and the Crohn's & Colitis Foundation announced an important collaboration today focused on the enhancement of clinical research in the area of ulcerative colitis and Crohn's Disease management. Together, they should speed the development of novel therapies for the millions of people who suffer from these chronic conditions.
Motivations and Goals for Cooperation

The collaboration intends to further clinical research about inflammatory bowel diseases (IBD), encompassing Crohn's disease and ulcerative colitis. Through their partnership, Azenta and the Crohn's & Colitis Foundation will be able to verify novel targets in the field and get innovative medications from the bench to the clinic.

They have a strong strategic interest in use their research to develop new therapeutics and advance the identification of new pharmaceutical targets in the immunological dysregulation and inflammation that drive these disorders.

  • Clinical Tests: Collaborative aspects of this strategy will include facilitate, accelerate, and/or sustenance of the fastest clinically justifiable patient access to the newest and valuable therapeutics.But the consequences of Crohn's disease and ulcerative colitis are felt by millions upon millions of people around the world, all of whom suffer terrible symptoms and see their quality of life greatly reduced. Due to the high level of commitment found in the Foundation towards IBD research and patient advocacy coupled with Azenta's innovative technological capabilities, this partnership is crucial.
  • Knowledge and Resources: Azenta provides cutting edge research instruments and knowledge, while the Crohn's & Colitis Foundation offers vital information on IBD and connections to a large patient and research community.

The alliance prioritises a patient-centric approach that ensures research activities are in line with the practical needs and experiences of those living with inflammatory bowel disease (IBD).

Expected Outcomes

The collaboration aims to achieve several significant outcomes:

  • Enhanced Drug Discovery: Utilizing advanced research techniques to discover new therapeutic targets and develop drugs that can effectively manage or cure IBD
  • Improved Clinical Practices: Generating data and insights that inform better diagnosis. Treatment and management of Crohn's disease and ulcerative colitis.
  • Increased Awareness and Education: Raising awareness about IBD. Educating patients caregivers and healthcare professionals about the latest advancements in research and treatment options.

Remarks from Important Parties

The transformational potential of this partnership was articulated by Andrés Hurtado-Lorenzo, PhD, Senior Vice President of Translational Research at the Crohn's & Colitis Foundation: "This partnership with Azenta represents significant step forward in our mission to find cures for IBD and improve the lives of patients." We can find innovative treatments more quickly and give hope to people afflicted by these diseases by pooling our capabilities."

With a focus on their commitment to funding innovative research that results in significant advancements in patient outcomes, Azenta Life Sciences echoed this confidence.

The collaboration between Azenta and Crohn's & Colitis Foundation marks promising advancement in the battle against Crohn's disease and ulcerative colitis. Through this partnership both organizations aim to drive research innovations. They want to deliver new effective treatments to patients. Ultimately, they work towards a future where these chronic conditions can be effectively managed or cured.